NO20091783L - Middel for a forebygge/behandle kreft - Google Patents

Middel for a forebygge/behandle kreft

Info

Publication number
NO20091783L
NO20091783L NO20091783A NO20091783A NO20091783L NO 20091783 L NO20091783 L NO 20091783L NO 20091783 A NO20091783 A NO 20091783A NO 20091783 A NO20091783 A NO 20091783A NO 20091783 L NO20091783 L NO 20091783L
Authority
NO
Norway
Prior art keywords
cancer cells
remedy
preventing
treating cancer
seq
Prior art date
Application number
NO20091783A
Other languages
English (en)
Norwegian (no)
Inventor
Shuji Sato
Tsutomu Oshima
Tomofumi Kurokawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44083820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091783(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2006/320429 external-priority patent/WO2007043635A1/ja
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20091783L publication Critical patent/NO20091783L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20091783A 2006-10-06 2009-05-05 Middel for a forebygge/behandle kreft NO20091783L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/JP2006/320429 WO2007043635A1 (ja) 2005-10-07 2006-10-06 癌の予防・治療剤
ARP070101453A AR060362A1 (es) 2005-10-07 2007-04-04 Agente para prevenir / tratar el cancer
JP2007100876 2007-04-06
PCT/JP2007/069908 WO2008044754A1 (en) 2006-10-06 2007-10-04 Prophylactic or therapeutic agent for cancer

Publications (1)

Publication Number Publication Date
NO20091783L true NO20091783L (no) 2009-07-01

Family

ID=44083820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091783A NO20091783L (no) 2006-10-06 2009-05-05 Middel for a forebygge/behandle kreft

Country Status (21)

Country Link
US (1) US20100008928A1 (de)
EP (1) EP2067791A4 (de)
JP (1) JPWO2008044754A1 (de)
KR (1) KR20090078339A (de)
CN (1) CN101541834A (de)
AR (1) AR063153A1 (de)
AU (1) AU2007307536A1 (de)
BR (1) BRPI0717024A2 (de)
CA (1) CA2666249A1 (de)
CL (1) CL2007002879A1 (de)
CO (1) CO6190538A2 (de)
EC (1) ECSP099276A (de)
IL (1) IL197389A0 (de)
MA (1) MA30816B1 (de)
MX (1) MX2009003126A (de)
NO (1) NO20091783L (de)
PE (1) PE20081456A1 (de)
RU (1) RU2009117237A (de)
TN (1) TN2009000090A1 (de)
TW (1) TW200823235A (de)
WO (1) WO2008044754A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103620032B (zh) * 2010-12-31 2016-02-24 生物蛋白有限公司 抗体的快速人源化
EP2740794B1 (de) * 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
EP3202419A1 (de) * 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig bindungsmittel zur modulation des hippo-pfads und verwendungen davon
WO2014069681A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2014069682A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
DK3653221T5 (da) * 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
MX2021000745A (es) 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
EP3908372A1 (de) * 2019-01-13 2021-11-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Für menschliches nectin-2 spezifische antikörper
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
BR112023015561A2 (pt) 2021-02-03 2023-11-14 Univ Minnesota Compostos imunoestimuiladores e conjugados
KR20240152879A (ko) * 2022-02-28 2024-10-22 넥틴 테라퓨틱스 리미티드 넥틴-2에 대한 인간화 항체 및 이의 약물 접합체
EP4518905A1 (de) 2022-05-06 2025-03-12 Seagen Inc. Immunmodulatorische antikörper-wirkstoff-konjugate
JP2025525904A (ja) 2022-08-03 2025-08-07 シージェン インコーポレイテッド 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
CN119096936A (zh) * 2024-08-28 2024-12-10 南方医科大学第三附属医院（广东省骨科研究院） 一种胆管癌足垫腘窝淋巴结自发转移动物模型的构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1999063063A1 (en) 1998-06-03 1999-12-09 Northwestern University Cellular proteins which mediate herpesvirus entry
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
DE19852800C1 (de) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
US20030022279A1 (en) * 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU1305302A (en) 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
EP1402053A4 (de) 2001-06-05 2005-05-11 Exelixis Inc Chds als modifikatoren des p53-wegs und verwendungsverfahren
EP1392111A4 (de) 2001-06-06 2004-07-28 Regeneron Pharma Verfahren zum targetting transkriptionell aktiver stellen
WO2003020743A1 (en) 2001-09-05 2003-03-13 Regeneron Pharmaceuticals, Inc. Methods of expressing transgenes
JP2005536190A (ja) * 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2070546A1 (de) * 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Vorbeugungsmaßnahmen/Heilmittel für Krebs

Also Published As

Publication number Publication date
TN2009000090A1 (en) 2010-08-19
IL197389A0 (en) 2011-08-01
EP2067791A4 (de) 2009-11-25
MX2009003126A (es) 2009-04-06
US20100008928A1 (en) 2010-01-14
TW200823235A (en) 2008-06-01
AR063153A1 (es) 2008-12-30
WO2008044754A1 (en) 2008-04-17
CL2007002879A1 (es) 2008-06-27
ECSP099276A (es) 2009-06-30
MA30816B1 (fr) 2009-10-01
CO6190538A2 (es) 2010-08-19
CN101541834A (zh) 2009-09-23
BRPI0717024A2 (pt) 2014-03-11
AU2007307536A1 (en) 2008-04-17
RU2009117237A (ru) 2010-11-20
CA2666249A1 (en) 2008-04-17
AU2007307536A2 (en) 2009-04-30
PE20081456A1 (es) 2008-11-27
EP2067791A1 (de) 2009-06-10
KR20090078339A (ko) 2009-07-17
JPWO2008044754A1 (ja) 2010-02-18

Similar Documents

Publication Publication Date Title
NO20091783L (no) Middel for a forebygge/behandle kreft
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
MA32539B1 (fr) Traitement du diabète chez des patients pour lesquels une thérapie par la metformine n'est pas appropriée
Wei et al. Characterization of cathepsin B gene from orange-spotted grouper, Epinephelus coioides involved in SGIV infection
BR112013021236A8 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
CA2793647A1 (en) Prophylaxis of colorectal and gastrointestinal cancer
EA201000329A1 (ru) Циклические депсипептиды
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
EA201391005A1 (ru) Слитый белок против злокачественной опухоли
MA35038B1 (fr) Association d'un inhibiteur de phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
JOP20210093A1 (ar) جسم مضاد fn14 غير متوافق مع الإنسان
DE602007012743D1 (de) Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs
US9109023B2 (en) Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP)
AR060362A1 (es) Agente para prevenir / tratar el cancer
JOP20210087A1 (ar) طرق علاج مرض الكلى المزمن باستخدام داباغليفلوزين
NZ583429A (en) Peptides and proteins capable of inhibiting and/or preventing mast cell activation
MX2023014669A (es) Compuestos utiles en el tratamiento o prevencion de un trastorno mediado por prmt5.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application